Pharmaceutical companies are making a strong case to both the Trump administration and European Union officials, asking to exclude medical goods from any new tariff impositions. They argue that including these goods could cause price surges on crucial medications such as Novo Nordisk’s Wegovy and Merck’s Keytruda, manufactured in Europe.
About the Author
